Drug intelligence / Profile preview

ZW437

Development stage: Preclinical
Lead developer: Zymeworks
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ZW437 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Zymeworks. It is part of a novel pan-RAS inhibitor ADC platform designed to target and treat cancers harboring RAS mutations. By combining a targeted antibody with a cytotoxic payload, ZW437 aims to selectively deliver therapy to tumor cells expressing specific markers associated with RAS-mutated pathways. As of early 2026, the drug is in preclinical development, with initial data scheduled for presentation at the American Association for Cancer Research (AACR) Annual Meeting in April 2026.

Targets

HRAS (H-Ras protein)

Beyond the preview

Go deeper on ZW437.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZW437.

Explore the full profile